Scienza e Tecnologia
Scantox Group acquires Gentronix, a world leader in genetic toxicology
For 25 years, Gentronix has provided genetic toxicology solutions to the global pharma, biotech and agrichem industries; enabling clients to optimize their development programs by enabling early identification of genotoxic compounds and supporting late-stage development phases with GLP studies. Gentronix offers a comprehensive portfolio of screening and regulatory genotoxicity assays and services, not least the OECD 488 Big Blue® Transgenic Rodent Mutation assay, as one of only three global providers. Further, Gentronix has expertise and services within ocular and skin toxicology endpoints.
Founded in 1999 by Prof. Richard Walmsely , Gentronix is located within the North West UK at the Alderley Park and employs close to 70 employees after a significant scale-up over the past 5 years.
says Jeanet Løgsted, CEO of Scantox Group.
Matt Tate , CEO of Gentronix, adds:
Gentronix Ltd will continue to operate under the current company name, expanding its service offering within specialist regulatory toxicology. With this acquisition the Scantox Group will employ more than 400 people across seven European sites offering first in class lead optimization, regulatory toxicology and CMC (Chemical, Manufacturing, Controls), formulation and analytical services.
Nicholas Hooge , Partner at Impilo, concludes,
Jeanet Løgsted, CEO of Scantox, jln@scantox.com
Matt Tate , Managing Director of Gentronix, part of Scantox Group, matthew.tate@gentronix.co.uk
View original content to download multimedia: https://www.prnewswire.co.uk/news-releases/scantox-group-acquires-gentronix-a-world-leader-in-genetic-toxicology-302240514.html